Guidance

6 Recommendations for further research

6 Recommendations for further research

6.1 The Committee considered that the following research would be of value:

Studies investigating the effectiveness of rituximab plus fludarabine and cyclophosphamide in people with relapsed and refractory chronic lymphocytic leukaemia that has previously been treated with rituximab.

Studies investigating the effectiveness of rituximab plus chemotherapy other than fludarabine and cyclophosphamide in people with relapsed and refractory chronic lymphocytic leukaemia.

Studies investigating the health-related quality of life of people with chronic lymphocytic leukaemia that include data collected using a generic preference-based measure.